Future Targets

Additional Planned Disease Targets

Planned Programs

•   Bi-specific antibody against enterovirus 68 and 71.

•   MAb prophylactic cocktail against RSV.

•   MAb against Crimean Congo Hemorrhagic Fever (CCHF).

•   Fusion protein post-infection treatment against gram-negative bacteria.

•   MAbs against Lassa, Junín viruses.

•   MAb cocktails against coccidioidomycosis, aspergillus, candida albicans.

•   Biologics against Leishmaniasis, Buruli Ulcer, Rabies and Snake bite toxins.

We are actively pursuing partnerships with organizations that have mission compatible developed
or controlled biologics programs, including those that are not moving forward due to strategic or
economic reasons.